The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer.
R. Yerushalmi
No relevant relationships to disclose
B. Dong
No relevant relationships to disclose
J. W. Chapman
No relevant relationships to disclose
P. E. Goss
Honoraria - GlaxoSmithKline; Novartis; Pfizer
M. N. Pollak
No relevant relationships to disclose
M. J. Burnell
No relevant relationships to disclose
V. H. Bramwell
No relevant relationships to disclose
M. N. Levine
No relevant relationships to disclose
K. I. Pritchard
Consultant or Advisory Role - Abraxis BioScience; Boehringer Ingelheim; Novartis; Pfizer; Roche
Honoraria - Abraxis BioScience; Boehringer Ingelheim; Novartis; Pfizer; Roche
Expert Testimony - AstraZeneca (U); Novartis (U)
T. J. Whelan
No relevant relationships to disclose
J. N. Ingle
Consultant or Advisory Role - Pfizer (U)
W. Parulekar
No relevant relationships to disclose
L. E. Shepherd
No relevant relationships to disclose
K. A. Gelmon
Honoraria - AstraZeneca; Pfizer